Capecitabine and Oxaliplatin (XELOX) for the Treatment of Patients with Metastatic Gastric Cancer and Severe Liver Dysfunction
The Korean Journal of Internal Medicine
; : 252-255, 2006.
Article
em En
| WPRIM
| ID: wpr-223932
Biblioteca responsável:
WPRO
ABSTRACT
Gastric cancer patients with severe liver dysfunction secondary to hepatic metastases have limited treatment options. Most cytotoxic drugs have a narrow therapeutic index. Although both capecitabine and oxaliplatin have been well tolerated as single agents for patients with severe hepatic dysfunction, the combination of these drugs has not been investigated. We report here on a case of successful treatment of a patient suffering with severe liver dysfunction and metastatic gastric cancer; the patient was treated with a combination of capecitabine and oxaliplatin (XELOX). The initial bilirubin level of the patient was 10.9 mg/dL. After two cycles of treatment, his bilirubin level decreased to 2.1 mg/dL. He has experienced an excellent radiological response and he has received six cycles of XELOX chemotherapy. XELOX chemotherapy is feasible and it can be associated with positive outcomes for the patients suffering with metastatic gastric cancer and severe liver dysfunction.
Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Compostos Organoplatínicos
/
Neoplasias Gástricas
/
Pró-Fármacos
/
Adenocarcinoma
/
Seguimentos
/
Falência Hepática
/
Desoxicitidina
/
Quimioterapia Combinada
/
Fluoruracila
/
Gastrectomia
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Humans
/
Male
Idioma:
En
Revista:
The Korean Journal of Internal Medicine
Ano de publicação:
2006
Tipo de documento:
Article